US Patent 11,419,769: Apomorphine Sublingual Film Claims, Scope, Expiration Risk and Patent Landscape
US Patent 11,419,769 protects a narrowly defined sublingual apomorphine film rather than apomorphine generally. Independent claim 1 requires an acid-addition salt of apomorphine, two specified molecular-weight polymer populations, a bilayer structure, and pyridoxine as the pH-neutralizing agent. The dependent claims add permeation enhancers, glycerol monostearate, plasticizers, starch derivatives, antioxidants, particle-size limits, stability requirements, pH limits, and three apomorphine hydrochloride dose ranges.
The patent is closely aligned with the formulation technology used for KYNMOBI, the FDA-approved apomorphine hydrochloride sublingual film for treating "OFF" episodes in Parkinson's disease. Patent infringement risk is highest for a product that reproduces the claimed bilayer architecture, pyridoxine-containing neutralizing layer, polymer ranges, and apomorphine hydrochloride dosage strengths.
What does US Patent 11,419,769 protect?
The patent protects a pharmaceutical composition in unit-dose sublingual film form with five core technical requirements:
| Claim 1 limitation |
Required scope |
| Dosage form |
Unit dosage form formulated for sublingual administration |
| Physical form |
Film |
| Active ingredient |
30% to 75% w/w acid-addition salt of apomorphine |
| Low-molecular-weight polymer |
0.5% to 10% w/w; 5 kDa to 50 kDa molecular weight |
| High-molecular-weight polymer |
4% to 20% plus stated tolerance language; greater than 60 kDa |
| Polymer identity |
Hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, or methyl cellulose |
| Film architecture |
Bilayer film |
| Neutralizing layer |
Second layer containing pyridoxine |
The claim is cumulative. A product must satisfy every limitation of claim 1 to infringe that claim literally. A product containing apomorphine in a sublingual film but lacking pyridoxine in a second layer would not literally satisfy the express bilayer limitation.
The claim also requires two polymer molecular-weight classes. The low- and high-molecular-weight polymers may be different cellulose derivatives, or potentially the same polymer chemistry supplied in distinct molecular-weight grades. The claim language does not require a particular ratio between the low- and high-molecular-weight polymers.
How does the claim structure affect infringement risk?
The independent composition claim is narrower than a claim directed broadly to apomorphine films. Its principal limitations create several potential design-around paths:
- Use a monolayer film rather than a bilayer film.
- Use a pH modifier other than pyridoxine.
- Use a polymer outside the listed cellulose-derivative group.
- Eliminate the two molecular-weight polymer populations.
- Use polymer concentrations outside the claimed ranges.
- Deliver apomorphine through a tablet, wafer, gel, spray, capsule, or another dosage form.
- Use a non-acid-addition form of apomorphine, subject to separate patent rights.
- Use a buccal or oral product that does not meet the sublingual administration limitation.
Doctrine-of-equivalents risk remains fact-specific. A formulation that substitutes another vitamin or buffering compound for pyridoxine could still generate litigation if the substitute performs substantially the same function in substantially the same way with substantially the same result. The express selection of pyridoxine, however, gives the patent owner an argument that the claim deliberately excludes other neutralizing agents.
What do claims 2 through 19 add?
The dependent claims create narrower fall-back positions around the commercial formulation.
| Claims |
Added limitation |
Commercial significance |
| 2 |
0.2% to 5% permeation enhancer |
Supports rapid transmucosal delivery |
| 3 |
0.2% to 5% glycerol monostearate |
Adds a specific excipient and film-performance limitation |
| 4-6 |
3% to 12% plasticizer; polyol, oleic acid, or triacetin |
Covers flexibility, handling and dissolution properties |
| 7-9 |
1% to 50% hydrolyzed starch, including dextrin or maltodextrin |
Covers film-forming and processing excipients |
| 10-11 |
Antioxidant or 0.05% to 2.5% metabisulfite |
Addresses apomorphine oxidation |
| 12 |
At least two months' stability at 40°C in sealed plastic-lined aluminum foil |
Links composition scope to packaging and accelerated stability |
| 13-15 |
Apomorphine particles; hydrochloride salt; 20 nm to 10 µm effective particle size |
Covers particle engineering and dissolution performance |
| 16 |
pH of 4.5 to 8.5 after placement in 1 mL unbuffered water at pH 7 |
Limits the acid-base behavior of the finished film |
| 17 |
Approximately 12 mg apomorphine hydrochloride |
Dose-specific protection |
| 18 |
Approximately 22 mg apomorphine hydrochloride |
Dose-specific protection |
| 19 |
Approximately 30 mg apomorphine hydrochloride |
Dose-specific protection |
Claims 17 through 19 are commercially important because they can track marketed dose strengths. The claims specify apomorphine hydrochloride amounts, not necessarily the amount of active apomorphine base. A product label using equivalent salt amounts must be assessed against the claim's measurement convention and manufacturing specifications.
What does the bilayer requirement mean?
The claim requires a first layer containing the acid-addition salt of apomorphine and a second layer containing pyridoxine. The claim does not state that pyridoxine must be absent from the first layer, nor does it expressly require a separate physical backing layer. The critical issue is whether the product has two identifiable film layers with the claimed allocation of ingredients.
A laminated or co-cast bilayer may fall within the claim if the layers remain materially distinct. A single homogeneous film containing both apomorphine and pyridoxine presents a stronger non-infringement position against the literal bilayer limitation, although the manufacturing process and final microstructure would matter.
The patent therefore reaches beyond the active ingredient. It protects the spatial organization of the formulation:
- apomorphine is concentrated in one layer;
- pyridoxine is placed in another layer;
- the two polymer populations control film formation and dissolution;
- pH adjustment is incorporated into the dosage form rather than left entirely to saliva.
What is the significance of pyridoxine?
Pyridoxine, or vitamin B6, is the expressly claimed pH-neutralizing agent. In an apomorphine hydrochloride film, pyridoxine can help moderate acidity and support tolerability or dissolution behavior. Claim 1 makes pyridoxine a mandatory limitation, not an optional excipient.
This creates an important distinction between:
- a formulation using pyridoxine as the neutralizer;
- a formulation using another base or buffer;
- a formulation with no dedicated neutralizing layer.
The latter two categories may avoid literal infringement of claim 1 but could remain exposed to other patents in the same family or to claims with broader pH-modifier language.
How do the particle-size and pH claims affect product scope?
Claim 15 covers apomorphine particles with an effective particle size from 20 nm to 10 µm. The term "effective particle size" can require technical interpretation. It may refer to a measured particle-size distribution rather than a single particle diameter. Analytical method, dispersion medium, agglomeration, and sampling conditions can affect the result.
Claim 16 requires a solution pH between 4.5 and 8.5 when the film is placed in 1 mL of unbuffered water at pH 7. That limitation is test-dependent. A party evaluating infringement would need to control:
- water quality;
- temperature;
- equilibration time;
- film mass;
- agitation;
- pH meter calibration;
- whether the entire film dissolves before measurement.
Claims 12, 15 and 16 can therefore create evidentiary disputes even when the formulation appears compositionally similar.
What method-of-use protection does US 11,419,769 provide?
Claim 20 covers a method of treating Parkinson's disease by sublingually administering the composition of claim 1. Claim 21 narrows the treatment to alleviating an "OFF" episode.
The method claims require use of the claimed composition. They do not cover every sublingual apomorphine product used in Parkinson's disease. A competing product would need to satisfy claim 1 before the treatment-use limitations become relevant.
The method claims may have regulatory significance in an abbreviated new drug application if the branded label includes treatment of Parkinson's disease "OFF" episodes. A generic applicant could pursue a Paragraph IV certification against listed method-of-use patents or use a section viii statement for a patented indication, depending on the Orange Book listing and label carve-out feasibility. FDA-approved apomorphine products and their labeling must be reviewed separately from the patent claims. FDA identifies KYNMOBI as apomorphine hydrochloride sublingual film for intermittent treatment of "OFF" episodes in patients with Parkinson's disease. (U.S. Food and Drug Administration, 2023)
What is the likely patent expiration date?
US Patent 11,419,769 was issued on August 23, 2022. The expiration date cannot be determined from the claims alone because the controlling term depends on the earliest effective nonprovisional or international filing date, continuation-chain treatment, patent-term adjustment, terminal disclaimers, and any patent-term extension.
The relevant term analysis is:
| Issue |
Effect on expiration |
| Earliest effective filing date |
Establishes the base 20-year term for the relevant application family |
| Continuation status |
Usually does not reset the 20-year term |
| Patent-term adjustment |
Can extend the base term for USPTO delay |
| Terminal disclaimer |
Can shorten the term to match an earlier patent |
| Patent-term extension |
May extend a qualifying regulatory patent term |
| Maintenance fees |
Failure to pay can cause expiration or lapse before the statutory term |
A reliable expiration date requires the USPTO patent-term data and the complete family prosecution history. The patent number and claim text alone do not establish the final enforceable expiration date.
What is the Orange Book status of US 11,419,769?
The patent number alone does not establish an Orange Book listing. Orange Book inclusion depends on whether the NDA holder submitted the patent to FDA, whether FDA accepted the listing, and whether the patent is listed against the relevant drug product and use.
For a KYNMOBI-related analysis, the relevant review should compare:
- patents listed for the KYNMOBI NDA;
- listed claims covering composition, formulation, method of use or drug substance;
- listed expiration dates;
- pediatric exclusivity;
- any delisting or correction history;
- whether the listed patent claims read on all approved strengths or only selected uses.
FDA's Orange Book provides the regulatory listing framework, while the patent itself controls claim scope. A patent can be relevant to a product without being listed in the Orange Book, and an Orange Book listing does not establish ultimate validity or infringement. (FDA, 2024)
How strong is the patent estate around this formulation?
US 11,419,769 has meaningful product-specific value but a limited literal scope.
Strengths
- It claims a complete dosage-form architecture rather than an isolated excipient.
- The bilayer and pyridoxine limitations can map directly to a commercial product design.
- Claims 17 through 19 target three specific apomorphine hydrochloride dose ranges.
- Claims 12, 15 and 16 provide additional technical limitations for stability, particle size and pH.
- The formulation claims can create ANDA exposure even when a generic manufacturer develops a different manufacturing process.
Weaknesses
- The claim contains multiple narrow limitations that create design-around opportunities.
- The polymer lists are closed-ended under conventional claim interpretation because they use "selected from the group consisting of."
- A competitor may avoid the claim with a different polymer, different neutralizer or monolayer structure.
- The claim's "4 to 20±6%" language requires prosecution-history review. The notation may reflect a drafting or transcription issue, a range with tolerance, or an amendment convention. Its legal meaning cannot be fixed solely from the supplied text.
- Stability and pH claims may be difficult to prove without standardized testing.
- Narrow formulation claims can face written-description, enablement, indefiniteness, anticipation and obviousness challenges if the prior art discloses overlapping excipients, polymer ranges or bilayer films.
Which companies are challenging the patent?
The supplied information identifies no Paragraph IV certification, ANDA applicant, district-court action, inter partes review, post-grant review, or settlement agreement involving US 11,419,769.
A complete challenger analysis requires matching the patent against:
- FDA Paragraph IV litigation notices;
- district-court docket records;
- Federal Circuit decisions;
- PTAB proceedings;
- Orange Book patent-listing data;
- ANDA settlement disclosures;
- SEC filings by the NDA holder and generic applicants.
The patent number alone does not establish that a generic company has challenged the patent. No conclusion about a live challenge or settlement should be drawn solely from the claims.
Are biosimilar risks relevant?
No. KYNMOBI is a chemically synthesized small-molecule drug containing apomorphine hydrochloride, not a biologic. Biosimilar approval under the Public Health Service Act is therefore not the relevant pathway.
The competitive threat is an ANDA-based generic or an alternative 505(b)(2) product. The main barriers are formulation equivalence, sublingual performance, dose uniformity, film manufacturing, stability, drug-product patent claims and any Orange Book-listed method-of-use patents.
What manufacturing and intellectual-property barriers exist?
The most important manufacturing barriers are:
- controlled separation of two film layers;
- uniform loading of apomorphine hydrochloride;
- prevention of apomorphine oxidation;
- control of particle size and agglomeration;
- reproducible polymer molecular-weight grades;
- film mechanical strength and flexibility;
- packaging that limits moisture and oxygen exposure;
- validation of accelerated stability;
- consistent dissolution and sublingual residence time.
These barriers may support commercial differentiation even where a competitor avoids literal claim coverage. Manufacturing know-how, batch records, analytical methods, supplier specifications and trade secrets can provide protection beyond the patent claims.
How does this patent compare with a broad apomorphine patent?
| Protection type |
US 11,419,769 |
Broad apomorphine patent |
| Active ingredient |
Acid-addition salt of apomorphine |
May cover apomorphine or a broader salt class |
| Dosage form |
Sublingual film |
Could cover multiple dosage forms |
| Layer structure |
Mandatory bilayer |
May not require layers |
| Neutralizer |
Pyridoxine required |
Could cover broader buffers or pH modifiers |
| Polymer limitations |
Two molecular-weight classes from listed cellulose derivatives |
May be broader or absent |
| Dose protection |
12, 22 and 30 mg hydrochloride ranges |
May cover a broader dosing regimen |
| Design-around risk |
Relatively high |
Depends on claim breadth |
| Product relevance |
High for matching film products |
Broader platform relevance |
The patent is best viewed as a formulation and product patent. It is not a basic apomorphine composition patent and does not, by itself, block every route of administering apomorphine.
Key Takeaways
- US 11,419,769 requires a bilayer sublingual film containing an acid-addition salt of apomorphine and pyridoxine in the second layer.
- Claim 1 also requires specified low- and high-molecular-weight cellulose polymers and concentration ranges.
- Claims 17 through 19 target approximately 12 mg, 22 mg and 30 mg of apomorphine hydrochloride.
- The patent is commercially relevant to KYNMOBI-type products but does not cover all apomorphine formulations.
- A monolayer film, non-pyridoxine neutralizer, different polymer system or non-film dosage form may provide design-around routes.
- The method claims are limited to use of the claimed composition for Parkinson's disease, including "OFF" episodes.
- Orange Book status, final expiration, Paragraph IV challenges and settlement activity cannot be established from the claim text alone.
- Biosimilar risk is not relevant; generic ANDA and 505(b)(2) competition are the applicable pathways.
- The "4 to 20±6%" limitation requires review of the issued patent, prosecution history and any certificate of correction before relying on a precise numerical construction.
FAQs
Does US 11,419,769 cover apomorphine tablets?
No. The asserted claims require a sublingual film. A tablet would not literally satisfy the dosage-form limitation.
Can a generic use a different pH-neutralizing agent?
Potentially. A product using a neutralizer other than pyridoxine may avoid literal infringement of claim 1, but the full patent family and any other listed patents would need separate review.
Does the patent cover apomorphine base?
The claims provided require an acid-addition salt of apomorphine. Apomorphine base is not within that express limitation.
Is a 30 mg apomorphine hydrochloride film automatically infringing?
No. The product must also satisfy the other limitations, including the bilayer structure, pyridoxine-containing second layer and polymer requirements.
Can a company avoid the patent by changing only the packaging?
Usually not if the finished dosage form still satisfies the composition claims. Packaging changes may be relevant to claim 12's stability limitation, but they do not necessarily avoid claim 1.
References
-
U.S. Patent No. 11,419,769. (2022). Pharmaceutical composition in unit dosage form formulated for sublingual administration. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2023). KYNMOBI (apomorphine hydrochloride) sublingual film prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
